Kymera Therapeutics

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

Company also presenting at upcoming investor conferences WATERTOWN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will